{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of October 2023): Yes\nDescription: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson & Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu\nURL: https://www.janssen.com/clinical-trials/transparency"],"condition":["Advanced or Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Advanced Or Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2730981"],"location":["Puerto Rico","United States","United Kingdom","Malaysia","Spain","Canada","South Korea","Belgium","China","Taiwan","Italy","Australia","France","Germany"],"study_start_month":["7"],"keyword":["Irinotecan","Amivantamab-vmjw","Oxaliplatin","Leucovorin","Amivantamab","Fluorouracil"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer","description":"The purpose of this study is to assess the anti-tumor activity of amivantamab as a monotherapy (Cohorts A, B, and C), to characterize the safety of amivantamab when added to standard-of care (SoC) chemotherapy in participants with metastatic colorectal cancer (mCRC) (Ph2 cohorts), and to assess the recommended phase 2 combination dose (RP2CD) of amivantamab when added to SoC chemotherapy (Ph1b cohorts).","dates":{"creation":"2022-07-15"},"accession":"2730981","cross_references":{"ClinicalTrials___gov":["NCT05379595"],"EU Clinical Trials Register":["2021-006629-23"]}}